Biomarkers
Wenora Y. Johnson, 3-time survivor, shares her cancer story and encourages patients to ask their care team about biomarker testing. Read More ›
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL). Read More ›
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer. Read More ›
By Dana Taylor
Read about important advancements in tumor biomarkers and their role in guiding treatment in some types of cancer. Read More ›
In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker. Read More ›
The understanding of the role of dMMR or MSI-H biomarkers in cancer has led to the first approval of a cancer drug based on a biomarker instead of a specific tumor type.
Read More ›
Biomarkers are biologic markers that indicate changes in our genes and may increase the risk of cancer. Read More ›
Wenora Y. Johnson, 3-time survivor, shares her cancer story and encourages patients to ask their care team about biomarker testing. Read More ›
By Tracy Wright
A new study that included 500 women with uterine cancer diagnosed between 1981 and 2007 led to the discovery of a biomarker that may be able to identify those who are at high risk for uterine cancer recurrence. Read More ›